Legend Biotech Corporation

12/09/2024 | Press release | Distributed by Public on 12/09/2024 19:03

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.